• Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights

  • Community Resources

  • Our Expert Network

CME & EducationAbout Us
Loading...
CME & EducationAbout Us
Loading profile...
  • Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights
  • Community Resources

  • Our Expert Network
  1. Home
  2. Videos
  3. Discourses In Dermatology
  4. World Mental Health Day Dermatology Role Addressing Mental Health Impacts

World Mental Health Day: Dermatology's Role in Addressing Mental Health Impacts

Featuring:
NBNicholas Brownstone, MDFaculty
Updated:Oct 10, 2024
DermatologyDermatology

About this video

In this episode of Topical Conversations, Dr Nick Brownstone highlights the critical role dermatologists play in addressing the mental health impact of skin conditions. For World Mental Health Day on October 10, Dr Brownstone emphasizes the importance of raising awareness about how dermatologic diseases affect patients' mental well-being. 

Mental health and skin disease: a quality-of-life issue 

Dr Brownstone opened by reminding dermatologists that while skin conditions like acne, psoriasis, atopic dermatitis, alopecia areata, and vitiligo may not be life-threatening, they can drastically reduce a patient's quality of life and urging his colleagues to consider the potential mental toll these conditions can take on patients. 

He stressed the importance of dermatologists taking a moment to ask their patients a simple but impactful question: Is this condition significantly affecting your quality of life? Many patients may be hesitant to proactively raise this issue, and such a question can open the door to discussions about their mental health and how their skin condition impacts their daily life. 

The connection between dermatology and mental health 

Dr Brownstone cited recent studies that have confirmed the negative mental health impacts associated with dermatologic conditions. One finding, published in JAMA Dermatology, demonstrated that patients with atopic dermatitis had a higher prevalence of suicidal ideation and attempts compared to the general population. He noted the seriousness of this finding, emphasizing that dermatologists must be mindful of these risks when treating patients with chronic skin diseases. 

Another study discussed by Dr Brownstone was the Global Valiant Study on vitiligo, also published in JAMA Dermatology. The study found that patients with vitiligo often find difficulty with everyday activities, such as choosing clothing or going to the beach, due to the psychological burden of their condition. These daily limitations, often overlooked, can severely impact their quality of life, highlighting the need for dermatologists to acknowledge the emotional and psychological effects of skin diseases. 

Addressing mental health in dermatology: simple and effective steps 

Dr Brownstone advised dermatologists to take 2 simple steps when a patient expresses that their skin condition is negatively impacting their mental health: 

  1. Offer more aggressive therapy: For patients whose current treatments may not be addressing their symptoms sufficiently, considering more intensive options could help improve both their physical and mental well-being. 
  2. Provide mental health support: If a patient's condition is having a severe psychological impact, dermatologists should not hesitate to recommend mental health resources. Dr Brownstone emphasized the value of referring patients to therapists or connecting them with patient support organizations. He mentioned several helpful resources, including the National Psoriasis Foundation, National Eczema Foundation, Vitiligo Research Foundation, and Global Vitiligo Foundation, all of which offer support and community for patients dealing with the emotional burden of their skin conditions. 

World Mental Health Day: a reminder for all healthcare providers 

Dr Brownstone concluded the discussion by urging his colleagues to always be mindful of the mental health aspects of skin conditions, reminding dermatologists to ask about mental health regularly and act when necessary. By addressing the often-overlooked psychological toll that skin diseases can take, dermatologists can help improve not only their patients' skin health but also their overall well-being, making a lasting difference in their quality of life.

1
Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma
5:04

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

2
What Changes When We Treat Psoriasis as Systemic Disease?
7:01

What Changes When We Treat Psoriasis as Systemic Disease?

3
Who to Look for and When to Act
2:31

Who to Look for and When to Act

4
How Oral TYK2 Inhibition Is Showing Up in Real Decisions
10:38

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

5
Injecting on Bone: A Practical Approach to Filler Safety
0:44

Injecting on Bone: A Practical Approach to Filler Safety

6
Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study
8:12

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

7
Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
2:51

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

8
Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
2:42

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

9
Bullous Pemphigoid: The Evolving Treatment Landscape
8:22

Bullous Pemphigoid: The Evolving Treatment Landscape

10
Confirming BP Diagnosis and Choosing Treatment
7:42

Confirming BP Diagnosis and Choosing Treatment

11
How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC
4:08

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

12
What Four Years Can Tell Us About Treating Moderate to Severe HS
3:29

What Four Years Can Tell Us About Treating Moderate to Severe HS

13
Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib
3:18

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

14
A Review of Dermoscopy Techniques With Michelle Tarbox, MD
1:28

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

15
Leading With Intention in Aesthetic Assessment
2:57

Leading With Intention in Aesthetic Assessment

16
Recognizing Bullous Pemphigoid Earlier in Clinical Practice
1:52

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

17
Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration
10:34

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

18
Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso
23:00

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

19
Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma
8:33

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

20
Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test
6:53

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

21
Topical Truths: Managing AD in the Real World
21:54

Topical Truths: Managing AD in the Real World

22
The Oral Conversation: How We Talk to Patients About Systemic Therapy Today
30:51

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

23
Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice
10:00

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

24
Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk
10:04

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

25
Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways
9:36

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

26
Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients
9:51

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

27
Fall Clinical Continuity Experience - Vtama - Lecture Recap Video
0:35

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

28
Four Years of Data: Durability and Distinction with TYK2 Inhibition
3:09

Four Years of Data: Durability and Distinction with TYK2 Inhibition

29
What an Oral Option Means for Psoriasis Care
2:34

What an Oral Option Means for Psoriasis Care

30
LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults
8:39

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

31
Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes
7:58

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

32
Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis
4:59

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

33
VTAMA: A New Standard in Psoriasis Management
4:59

VTAMA: A New Standard in Psoriasis Management

34
Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions
18:17

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

35
Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice
16:27

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

36
Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing
6:45

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

37
Psoriasis mechanism of disease: Pathogenesis
8:27

Psoriasis mechanism of disease: Pathogenesis

38
Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors
12:45

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved